These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 21881824)

  • 1. An imatinib-treated FIL1P1-PDGFRα chronic eosinophilic leukemia transforming to erythroid blast crisis: a case report.
    Papanikolaou X; Kotsopoulou M; Triantafillopoulou ID; Zoi A; Chatziantoniou V; Maltezas D; Mitsouli-Mentzikof C
    Ann Hematol; 2012 May; 91(5):785-787. PubMed ID: 21881824
    [No Abstract]   [Full Text] [Related]  

  • 2. [Endomyocardial fibrosis in chronic eosinophilic leukemia].
    Winter L; Zellweger MJ; Bremerich J
    Rofo; 2009 Jul; 181(7):691-3. PubMed ID: 19401974
    [No Abstract]   [Full Text] [Related]  

  • 3. Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome.
    Helbig G; Kyrcz-Krzemień S
    Am J Hematol; 2014 Jan; 89(1):115. PubMed ID: 24009127
    [No Abstract]   [Full Text] [Related]  

  • 4. Rapid reversion of eosinophilic gastroenteritis associated with FIP1L1-PDGFRA fusion after targeted therapy with imatinib.
    Pitini V; Sturniolo G; Cavallari V; Arrigo C
    Br J Haematol; 2006 Jan; 132(2):123. PubMed ID: 16398645
    [No Abstract]   [Full Text] [Related]  

  • 5. Imatinib-responsive hypereosinophilic syndrome.
    Robyn J
    Leuk Res; 2006 Aug; 30(8):915-6. PubMed ID: 16530830
    [No Abstract]   [Full Text] [Related]  

  • 6. Detection of FIP1L1-PDGFRA fusion by FISH.
    Ma ES; Wong KF; Wong CL; Siu LL
    Br J Haematol; 2007 Aug; 138(3):279. PubMed ID: 17542982
    [No Abstract]   [Full Text] [Related]  

  • 7. [Identification of clonal proliferation of T cell and FIP1L1-PDGFRalpha fusion gene in hypereosinophilic syndrome associated with lymphomatoid papulosis which showed rapid and complete response to the treatment with imatinib].
    Fujimi A; Kanisawa Y; Kikuchi S; Okuda T; Sato Y; Doi T; Ohta H; Umeda I; Nobuoka A
    Nihon Naika Gakkai Zasshi; 2007 Dec; 96(12):2794-7. PubMed ID: 18203417
    [No Abstract]   [Full Text] [Related]  

  • 8. FIP1L1-PDGFRα-positive hypereosinophilic syndrome in childhood: a case report and review of literature.
    Farruggia P; Giugliano E; Russo D; Trizzino A; Lorenzatti R; Santoro A; D'Angelo P
    J Pediatr Hematol Oncol; 2014 Jan; 36(1):e28-30. PubMed ID: 23337549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FIP1L1-PDGFRalpha in hypereosinophilic syndrome and mastocytosis.
    Gilliland G; Cools J; Stover EH; Wlodarska I; Marynen P
    Hematol J; 2004; 5 Suppl 3():S133-7. PubMed ID: 15190295
    [No Abstract]   [Full Text] [Related]  

  • 10. The results of imatinib therapy for patients with primary eosinophilic disorders.
    Helbig G; Stella-Holowiecka B; Grosicki S; Bober G; Krawczyk M; Wojnar J; Reiter A; Hochhaus A; Holowiecki J
    Eur J Haematol; 2006 Jun; 76(6):535-6. PubMed ID: 16608506
    [No Abstract]   [Full Text] [Related]  

  • 11. Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-a positive idiopathic hypereosinophilic syndrome.
    Martinelli G; Malagola M; Ottaviani E; Rosti G; Trabacchi E; Baccarani M
    Haematologica; 2004 Feb; 89(2):236-7. PubMed ID: 15003901
    [No Abstract]   [Full Text] [Related]  

  • 12. FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib.
    Wang LN; Pan Q; Fu JF; Shi JY; Jin J; Li JM; Hu J; Zhao WL; Chen Z; Chen SJ
    Chin Med J (Engl); 2008 May; 121(10):867-73. PubMed ID: 18706197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study.
    Baccarani M; Cilloni D; Rondoni M; Ottaviani E; Messa F; Merante S; Tiribelli M; Buccisano F; Testoni N; Gottardi E; de Vivo A; Giugliano E; Iacobucci I; Paolini S; Soverini S; Rosti G; Rancati F; Astolfi C; Pane F; Saglio G; Martinelli G
    Haematologica; 2007 Sep; 92(9):1173-9. PubMed ID: 17666373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concomitant FIP1L1-PDGFRA fusion gene and T-cell clonality in a case of chronic eosinophilic leukemia with clonal evolution and an incomplete response to imatinib.
    Burbury K; Chew LP; Westerman D; Catalano A; Seymour JF
    Leuk Lymphoma; 2011 Feb; 52(2):335-8. PubMed ID: 21281241
    [No Abstract]   [Full Text] [Related]  

  • 15. [FIP1L1-PDGFRalpha-positive myeloproliferative disease with hypereosinophilia: clinical characteristics and pathogenetic therapy].
    Nemchenko IS; Khoroshko ND; Turkina AG; Sokolova MA; Kokhno AV; Semenova EA; Zakharova AV
    Ter Arkh; 2005; 77(7):90-2. PubMed ID: 16116920
    [No Abstract]   [Full Text] [Related]  

  • 16. [Synchronous detection of T-cell clonality and FIP1L1-PDGFRA fusion gene in a hypereosinophilic syndrome].
    Martinaud C; Souraud JB; Cournac JM; Pons S; Ménard G; de Jaureguiberry JP; Brisou P
    Rev Med Interne; 2011 May; 32(5):e66-8. PubMed ID: 20633965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Oncogene Fip1-likeL/PDGFRalpha as a target for imatinib in patients with hypereosinophilic syndrome and chronic eosinophilic leukemia. A novel look at pathogenesis and therapy].
    Helbig G; Stella-Hołowiecka B; Hołowiecki J
    Pol Arch Med Wewn; 2005 May; 113(5):490-7. PubMed ID: 16479834
    [No Abstract]   [Full Text] [Related]  

  • 18. Antitumor activity of S116836, a novel tyrosine kinase inhibitor, against imatinib-resistant FIP1L1-PDGFRα-expressing cells.
    Shen Y; Ren X; Ding K; Zhang Z; Wang D; Pan J
    Oncotarget; 2014 Nov; 5(21):10407-20. PubMed ID: 25431951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The hypereosinophilic syndrome: idiopathic or not, that is the question.
    Cools J
    Haematologica; 2005 May; 90(5):582-4. PubMed ID: 15921372
    [No Abstract]   [Full Text] [Related]  

  • 20. Complete reversal of left ventricular mass in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia after therapy with imatinib.
    Volz HC; Weiss C; Lossnitzer D; Zankl AR; Perz JB; Dengler TJ; Katus HA; Hardt SE
    Int J Cardiol; 2011 Sep; 151(3):e90-2. PubMed ID: 20609486
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.